Morgan Stanley
BCAB icon

Morgan Stanley’s BioAtla BCAB Stock Holding History

Morgan Stanley’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59K Sell
1,108
-1
-0.1% -$4 ﹤0.01% 7233
2026
Q1 		$8.92K Buy
1,109
+236
+27% +$2.76K ﹤0.01% 6981
2025
Q4 		$24.8K Buy
873
+564
+183% +$22.1K ﹤0.01% 6624
2025
Q3 		$10.6K Sell
309
-6,002
-95% -$139K ﹤0.01% 6882
2025
Q2 		$125K Sell
6,311
-5,601
-47% -$114K ﹤0.01% 6049
2025
Q1 		$207K Sell
11,912
-10,177
-46% -$218K ﹤0.01% 5717
2024
Q4 		$653K Sell
22,089
-15,075
-41% -$1.27M ﹤0.01% 5310
2024
Q3 		$3.27M Buy
37,164
+69
+0.2% +$5.79K ﹤0.01% 4297
2024
Q2 		$2.54M Sell
37,095
-1,108
-3% -$132K ﹤0.01% 4399
2024
Q1 		$6.57M Sell
38,203
-59
-0.2% -$7.33K ﹤0.01% 3690
2023
Q4 		$4.71M Buy
38,262
+6,246
+20% +$541K ﹤0.01% 3964
2023
Q3 		$2.72M Sell
32,016
-1,822
-5% -$232K ﹤0.01% 4187
2023
Q2 		$5.08M Sell
33,838
-3,732
-10% -$642K ﹤0.01% 3769
2023
Q1 		$5.03M Buy
37,570
+1,143
+3% +$206K ﹤0.01% 3787
2022
Q4 		$15M Buy
36,427
+3,472
+11% +$1.44M ﹤0.01% 2633
2022
Q3 		$12.7M Buy
32,955
+11,379
+53% +$3.72M ﹤0.01% 2700
2022
Q2 		$3.08M Sell
21,576
-10,304
-32% -$1.64M ﹤0.01% 4179
2022
Q1 		$7.97M Buy
31,880
+18,675
+141% +$7.81M ﹤0.01% 3175
2021
Q4 		$13M Buy
13,205
+8,529
+182% +$10.9M ﹤0.01% 2635
2021
Q3 		$6.88M Buy
4,676
+4,397
+1,576% +$8.57M ﹤0.01% 3342
2021
Q2 		$591K Buy
+279
New +$630K ﹤0.01% 5418
2021
Q1 		– Sell
-4
Closed -$7K – 7485
2020
Q4 		$7K Buy
+4
New +$6.69K ﹤0.01% 6710

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's BCAB Position: Q2 2026 in Review

Morgan Stanley reduced its BioAtla (BCAB) stake by 0.09% in Q2 2026, selling an estimated $4 and leaving 1,108 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #7233.

Morgan Stanley first reported a position in BCAB in Q4 2020 and has held it in 22 quarters since. The position peaked at $15M in Q4 2022. 21 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

  • Morgan Stanley held 1,108 shares of BioAtla worth $4.59K as of Q2 2026.
  • Morgan Stanley sold 1 BioAtla share in Q2 2026, an estimated $4.
  • BioAtla made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7233 holding.
  • Morgan Stanley first reported a position in BioAtla in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's BioAtla position peaked at $15M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.